Xvivo Perfusion Valuation Multiples

Xvivo Perfusion Overview

About Xvivo Perfusion

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Founded

1998

HQ

Employees

158

Website

xvivoperfusion.com

Sectors

Medical DevicesHealthTechDeepTech

Financials (LTM)

Revenue: $97M

EBITDA: $20M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Xvivo Perfusion Financials

Xvivo Perfusion reported last 12-month revenue of $97M and EBITDA of $20M.

In the same LTM period, Xvivo Perfusion generated $72M in gross profit, $20M in EBITDA, and $7M in net income.

Xvivo Perfusion P&L

In the most recent fiscal year, Xvivo Perfusion reported revenue of $92M and EBITDA of $18M.

Xvivo Perfusion expects next 12-month revenue of XXX and NTM EBITDA of XXX

Xvivo Perfusion Stock Performance

Xvivo Perfusion has current market cap of $1B, and enterprise value of $1B.

Xvivo Perfusion's stock price is $32.86.

Xvivo Perfusion Valuation Multiples

Xvivo Perfusion trades at 10.5x EV/Revenue multiple, and 50.4x EV/EBITDA.

Xvivo Perfusion Financial Valuation Multiples

As of April 20, 2026, Xvivo Perfusion has market cap of $1B and EV of $1B.

Equity research analysts estimate Xvivo Perfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Xvivo Perfusion has a P/E ratio of 149.6x.

Xvivo Perfusion Margins & Growth Rates

Xvivo Perfusion's revenue in the last 12 month grew by 22%.

Xvivo Perfusion's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.

Xvivo Perfusion's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Xvivo Perfusion's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Xvivo Perfusion Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Xvivo Perfusion M&A Activity

Xvivo Perfusion acquired XXX companies to date.

Last acquisition by Xvivo Perfusion was on XXXXXXXX, XXXXX. Xvivo Perfusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Xvivo Perfusion Investment Activity

Xvivo Perfusion invested in XXX companies to date.

Xvivo Perfusion made its latest investment on XXXXXXXX, XXXXX. Xvivo Perfusion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).